S6 Ep35: Ross Reflects on Surgical Advances and Changing Trends in CRC
Dr Ross shares his advice to health care professionals regarding the detection and treatment of patients with colon cancer, unmet needs for this patient population, the role of minimally invasive surgery, and the need to address and overcome health disparities that affect this population.
11m Mar 10, 2022
11m
S6 Ep35: Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer
Dr Hurvitz sheds light on shifts in practice patterns in HER2-positive breast cancer in light of data that emerged in 2021, remaining questions regarding treatment sequencing, the importance of updates to the National Comprehensive Cancer Network guidelines in metastatic HER2-positive breast cancer, and future directions to keep an eye on in 2022.
10m Mar 03, 2022
10m
S6 Ep34: Jain Talks Patient Management, Dosing, and Toxicity Mitigation With Frontline PARP Maintenance in Ovarian Cancer
Dr Jain discusses the current utility of frontline maintenance therapy in advanced ovarian cancer, dosing strategies with PARP inhibitors, and management strategies for common adverse effects associated with these therapies.
9m Feb 24, 2022
9m
S6 Ep28: Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
Dr Milhem discusses the unique mechanism of action and delivery method of RP1, which is being evaluated in the IGNYTE trial for patients with solid tumors, as well as the parallel studies ARTACUS and CERPASS, which are further exploring the agent.
14m Feb 17, 2022
14m
S6 Ep33: Cleveland Clinic Faculty Speak to Shifting Standards in Hematologic Malignancies
We had the pleasure of speaking with faculty from an OncLive® Institutional Perspectives in Cancer webinar on hematologic malignancies, hosted in partnership with Cleveland Clinic, to discuss current practice patterns and emerging therapies in chronic myeloid leukemia, chronic lymphocytic leukemia, myelofibrosis, and acute lymphoblastic leukemia.
23m Feb 10, 2022
23m
S6 Ep32: Simon Shares Steps Towards Bridging Clinical Trial Disparities in Cancer
Melissa A. Simon, MD, MPH, discusses unmet needs regarding clinical trials for underserved populations with cancer, highlights the key objectives of the ECOG-ACRIN Health Equity Committee and the US Preventive Services Task Force, and shares her advice to health care professionals in the cancer space who are working to bridge some of these disparities.
11m Feb 07, 2022
11m
S6 Ep31: Rare Cancers Report: Pediatric Neuroblastoma
Dr Furman discussed the rarity of pediatric neuroblastoma, treatment options and expected outcomes for patients, and ongoing clinical trials in this space.
24m Feb 03, 2022
24m
S6 Ep30: Ramchandren Reviews the Rationale to Further Evaluate CLR 131 in Waldenström Macroglobulinemia
Dr Ramchandren discusses current treatment options for patients with Waldenström macroglobulinemia who have limited response to other therapies, the rationale for the expansion cohort of the phase 2 CLOVER-WaM trial evaluating CLR 131 in these patients, and other anticipated research trends in this paradigm.
12m Jan 31, 2022
12m
S6 Ep29: Sorting Through Sexism, Guilt, and Motherhood in Medicine
Drs Garg, Outlaw-Evans, and Farrington discuss their experiences as women in oncology, changes they have observed in the culture of medicine, and their advice to young women entering the field.
31m Jan 27, 2022
31m
S6 Ep27: Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management
Dr Wang discusses the clinical experience with ibrutinib in mantle cell lymphoma, its present role in the management of MCL, and ongoing research that may affect its use as a single agent.
21m Jan 20, 2022
21m
S6 Ep26: Research Reflections: Coombs Provides Insight Into Key ASH Abstracts in CLL
Dr Coombs discusses research that was presented at the 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with covalent and noncovalent BTK inhibitors, COVID-19 vaccinations, and time-limited combinations.
11m Jan 17, 2022
11m
S6 Ep25: Basu on Getting Ahead of the Shadow Curve of COVID-19 in Oncology
Dr Basu discusses the “shadow curve” that could result from disruptions in cancer care during the COVID-19 pandemic and innovative strategies that Cancer Treatment Centers of America are taking to avoid this.
15m Jan 13, 2022
15m
S6 Ep24: Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma
Dr Meyer discusses the rarity of cardiac angiosarcoma, optimizing detection strategies, surgical interventions, and chemotherapy for this patient population, and why immunotherapy has the potential to transform care for patients.
23m Jan 10, 2022
23m
S6 Ep23: Dietz Draws Attention to Gender Disparities in Breast Cancer
Dr Dietz discusses her experience as a woman in surgical oncology, the importance of bridging gender disparities, and her advice to women entering the health care industry.
29m Jan 06, 2022
29m
S6 Ep22: Gilbert on Gaining New Ground at Vanderbilt
Dr Gilbert discusses her new role as associate director for research, education, and professional development at Vanderbilt University Medical Center and shares some of her short- and long-term goals in this position.
14m Jan 03, 2022
14m
S6 Ep21: Bardia on Sacituzumab Govitecan’s Current and Potential Future Position in TNBC
Dr Bardia discusses the role of sacituzumab govitecan in the treatment of patients with metastatic triple-negative breast cancer, the influence of the National Comprehensive Cancer Network guidelines on treatment recommendations and sequencing in the second-line setting, and ongoing research with the agent in the neoadjuvant setting.
10m Dec 30, 2021
10m
S6 Ep21: Gasparetto Talks Management Strategies for Belantamab Mafodotin–Related Ocular Toxicity in Myeloma
Dr Gasparetto discusses the management of ocular toxicities associated with belantamab mafodotin, the nuances of dose modification, and the potential for retreatment following toxicity resolution.
10m Dec 27, 2021
10m
S6 Ep20: Phillips Reflects on Lessons Learned With BTK Inhibitors in MCL
Dr Phillips discusses the utility of ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma, the impact of long-term follow-up data with ibrutinib, and findings from the phase 3 SYMPATICO trial that could shake up the treatment paradigm.
12m Dec 23, 2021
12m
S6 Ep19: Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer
Dr. Schwartzberg discusses the rationale to evaluate enobosarm in AR-positive, ER-positive advanced breast cancer, phase 2 data with the agent, and expectations for the ongoing phase 3 ARTEST trial in this population.
19m Dec 20, 2021
19m
S6 Ep18: Hochster Underscores Headway Made in Gastric/GEJ Cancers
Dr. Hochster provides insight into the current gastric/GEJ landscape, spotlighting molecular testing approaches, the roles of chemoimmunotherapy combinations, ongoing research with biomarkers of response, and optimal treatment sequencing for patients with HER2-positive disease.
9m Dec 16, 2021
9m
S6 Ep17: Shah and Wang Share Insights Into Optimized CAR T-Cell Therapy in Hematologic Malignancies
Dr. Shah and Dr. Wang discuss the management of cytokine release syndrome and neurotoxicity, the referral process, and the need for academic and community collaboration for CAR T-cell therapy in hematologic malignancies.
27m Dec 13, 2021
27m
S6 Ep16: Coombs Previews Anticipated ASH Abstracts in CLL
Dr. Coombs discusses research that will be presented at the upcoming 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with covalent and noncovalent BTK inhibitors, COVID-19 vaccinations, and time-limited combinations.
16m Dec 09, 2021
16m
S6 Ep15: FDA Approval Insights: Adjuvant Pembrolizumab in RCC
Dr. Choueiri discusses the significance of the FDA approval of pembrolizumab as adjuvant therapy in renal cell carcinoma and key data from the pivotal phase 3 KEYNOTE-564 trial.
12m Dec 06, 2021
12m
S6 Ep14: Bleicher and Nardello Talk About Finding the Best Fit for Fellowship in Oncology
Dr. Bleicher and Dr. Nardello discuss the process of finding a mentor, what to look for in a fellowship program, and the benefits of fellowship for both academic and community oncologists.
47m Dec 02, 2021
47m
S6 Ep13: Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma
Sameek Roychowdhury, MD, PhD, discusses the pivotal phase 2 trial with infigratinib in FGFR-positive cholangiocarcinoma, the safety and efficacy achieved with infigratinib, and the next steps for this agent.
17m Nov 29, 2021
17m
S6 Ep12: Katona Highlights the Hallmarks of Hereditary Diffuse Gastric Cancer
Bryson Katona, MD, of Penn Medicine, discusses the hallmarks of hereditary diffuse gastric cancer.
24m Nov 25, 2021
24m
S6 Ep11: Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson
Dr. Allison highlights everything from his proudest professional moments, to MD Anderson’s Moon Shot program, to his musical talents, to next steps he’s taking in cancer research.
26m Nov 22, 2021
26m
S6 Ep10: Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.
18m Nov 18, 2021
18m
S6 Ep9: Ku Reviews Exciting ESMO Data in Gastric/GEJ Cancer
Dr. Ku underscores key takeaways from the CheckMate649 and DESTINY-Gastric02 trials in gastric/GEJ cancer and highlights ongoing research that has the potential to further inform treatment selection and sequencing in the field
12m Nov 15, 2021
12m
S6 Ep8: Gradishar Gives Insight Into the Growing Role of SERDs in Breast Cancer
Dr. Gradishar discusses the evolution of SERDs in breast cancer, novel SERDs that could shift the paradigm of breast cancer treatment, and ongoing research that could solidify the role of these agents in the field.
11m Nov 11, 2021
11m
S6 Ep7: Tagawa Breaks Down FGFR Testing and the Use of Erdafitinib in Bladder Cancer
Dr. Tagawa discusses the incidence and identification of FGFR alterations in bladder cancer, the approval and use of erdafitinib in the second-line setting for patients with advanced bladder cancer, and research directions with the FGFR inhibitor in the field.
21m Nov 08, 2021
21m
S6 Ep6: Yarchoan Talks Research Directions in Fibrolamellar Carcinoma
Dr. Yarchoan underscores the unique characteristics of fibrolamellar carcinoma, treatment options for these patients, and ongoing research efforts to expand the limited paradigm in this disease.
16m Nov 04, 2021
16m
S6 Ep5: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL
Dr. Shah discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia, key findings from the pivotal ZUMA-3 trial, and next steps with CAR T-cell therapy in the field.
15m Nov 01, 2021
15m
S6 Ep4: Jain and Spaggiari Speak to Surgical and Systemic Considerations for CRC Liver Metastases
Dr. Jain and Dr. Spaggiari highlight key advancements in the treatment of patients with colorectal cancer liver metastases, patient and disease factors to consider during surgical and systemic treatment decisions, and the importance of multidisciplinary care in this patient population.
17m Oct 28, 2021
17m
S6 Ep3: Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC
In our exclusive interview, Johnson discussed the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant NSCLC, and where the combination could be used in practice pending further positive study results.
9m Oct 25, 2021
9m
S6 Ep2: Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients
Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 vaccines, determinants of vaccine responses, and the potential need for booster vaccine dosing in this population.
23m Oct 21, 2021
23m
S6 Ep1: Ilson Delves Into the Development of Checkpoint Inhibition in Gastric/GEJ Cancers
Dr. Ilson discusses treatment sequencing for patients with gastric and gastroesophageal junction cancer, the integration of immunotherapy into the frontline setting, and key ongoing studies in the field.
19m Oct 18, 2021
19m
S5 Ep50: Gordan on Growing the Infrastructure for In-House Genomic Testing
Dr. Gordan discusses the advantages of in-house genomic testing, the transition from external to internal sequencing, and the anticipated effects of the move.
13m Oct 14, 2021
13m
S5 Ep49: DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
Dr. DeNunzio discusses how proton beam therapy is being used throughout oncology, the advantages of the modality and how it complements other treatment interventions, and where research with the therapy is headed.
10m Oct 11, 2021
10m
S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer
Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.
19m Oct 07, 2021
19m
S5 Ep47: FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.
17m Oct 04, 2021
17m
S5 Ep46: Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?
Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices
18m Sep 30, 2021
18m
S5 Ep45: Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC
Dr. Aggarwal and Dr. Girard discuss the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the study regimen in patients with unresectable stage III NSCLC.
27m Sep 27, 2021
27m
S5 Ep44: Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer
Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.
16m Sep 23, 2021
16m
S5 Ep43: Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC
Dr. Dietrich discusses the latest developments with immunotherapy and targeted therapy in stage III non–small cell lung cancer.
16m Sep 20, 2021
16m
S5 Ep42: Neel on Maximizing Research Strides in Oncology
Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and potential future directions throughout the field.
29m Sep 16, 2021
29m
S5 Ep41: Loaiza-Bonilla Offers Guidance on Optimizing Treatment Selection in Pancreatic Cancer
Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicities in treatment planning, and treatment options available to patients post gemcitabine-based regimens.
17m Sep 13, 2021
17m
S5 Ep40: Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer
Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.
17m Sep 09, 2021
17m
S5 Ep39: McKay Filters Through Frontline Treatment Considerations in mRCC
Dr. McKay discusses the importance of patient selection in advanced renal cell carcinoma, selecting between available combination regimens, and nuances regarding the timing of treatment in this disease.
17m Sep 06, 2021
17m
S5 Ep38: Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer
Dr. Sosa discusses the rise in thyroid cancer cases, patient risk factors, the financial challenges associated with long-term treatment and testing, and future research directions in the field.
18m Sep 02, 2021
18m